Overall survival and associated factors in women with metastatic breast cancer treated with trastuzumab at a public referral institution.

Rev Bras Epidemiol · 2023 · PMC10642446 · PMID 37878833

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendp=0.067so close (0.05 < p ≤ 0.1)

The absence of prior exposure to trastuzumab in adjuvant and/or neoadjuvant therapy showed a trend of association with longer survival (HR: 0.69; 95%CI 0.46–1.03; p=0.067).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.